ClinicalTrials.gg
TerminatedNCT05124873Updated Jun 17, 2025Results posted

Moisture Management Liner At-Home Evaluation

An interventional study of Moisture Management Liner in Amputation Stump, Amputation and Amputees, sponsored by Liberating Technologies, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2025-06-17.

Sponsored by Liberating Technologies, Inc. · Not applicable, Interventional, and Other

Why this study was terminated
Manufacturing delays and issues of the experimental liner due to the Covid-19 pandemic. Manufacturers unable to provide the remaining liners to the investigators in the required timeframe.
Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years to 89 Years
Sex
All
01

Study summary

The comfort and fit of the residual limb within a prosthetic socket are of primary concern for many amputees. The residual limb is typically covered by unbreathable and non-thermally conductive materials that can create a warm and ultimately moist environment.

The investigators have developed a silicone liner approach to passively conduct heat from the skin using thermally conductive elastomers. A technology that can provide thermal control while retaining adequate suspension, weight, and other prosthetic characteristics would benefit many prosthesis wearers.

Read the detailed description

The comfort and fit of the residual limb within a prosthetic socket are of primary concern for many amputees. The residual limb is typically covered by unbreathable and non-thermally conductive materials that can create a warm and ultimately moist environment. These layers consist of a prosthetic liner that rolls onto the limb and traps heat and occasional extra prosthetic socks. Studies found increases in socket temperature after the prosthesis was donned. Temperatures were found to remain elevated long after activity cessation and even a rest period of double the duration of the preceding activity period is insufficient to return the limb to its initial temperature. A small amount of activity can cause the socket temperature to elevate and remain at an uncomfortable level for an extended period of time, which can lead to decreased wear times. In summary, an uncomfortable socket/residual limb interface decreases prosthesis use among amputees who want to remain active in their lives.

The investigators have developed a silicone liner approach to passively conduct heat from the skin using thermally conductive elastomers. A technology that can provide thermal control while retaining adequate suspension, weight, and other prosthetic characteristics would benefit many prosthesis wearers.

This study will focus on investigating the efficacy of this novel moisture and thermal management (experimental) liner.

The rationale for this study is to determine how well the new technology can regulate the residual limb temperature and reduce the moisture generation in a home environment where the device would ultimately be utilized.

The objective of this study is to measure the effects of residual limb moisture and thermal management on quality of life (QoL) and functional outcomes. Reducing temperature increases of the residual limb inside the prosthetic socket would result in less sweating and greater comfort while wearing the prosthesis, and ultimately greater function and better quality of life as measured by standard functional and QoL outcome measures. The primary outcome measure is the modified Dermatology Quality Life Index (mDLQI). All other measures collected during this study are exploratory.

A prospective design will be implemented for this study. Research participants will be consented by LTI over the phone. Residual limb measurements will be received from the participant to confirm liner sizing. One 'experimental' prototype liner will be created for each participant. Subjects with a similar liner size and profile to the available experimental liners will be targeted. Temperature and step-count sensors will be placed on the participant's prosthesis to log daily measurements. Testing will consist of 2 site visits, with the entire study lasting approximately 5 weeks.

Lower limb prosthesis users will be recruited for the study and consented with an approved protocol. Research participants will represent a convenience sample and will reflect the local population of people with lower limb differences who use prosthetic sockets and could benefit from temperature control within the socket.

A maximum of 16 subjects will be recruited for this study. This sample size accounts for subject drop out and other losses (such as incomplete log data, etc.) to yield usable data from the target 12 subjects required by the power analysis.

02

Conditions studied

  • Amputation Stump
  • Amputation
  • Amputees
  • Lower Limb Deformity
  • Prosthesis User
  • Prosthesis

Keywords

  • Cooling
  • amputee
  • lower limb difference
  • Prosthetic
  • socket
  • Prosthesis
  • Prosthetist
  • Liner
  • sweat
  • walking
  • sock
  • leg
  • perspiration
  • moisture
  • heat
  • thermal
03

In context

Lead sponsor

Liberating Technologies, Inc. is the lead sponsor of 15 studies on the registry; 4 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Lower limb amputee
  • Be willing and able to complete the tasks outlined
  • Are at least 6 months on a lower-limb prosthesis
  • Fits within an experimental liner (cushion style liner and size 23.5-28 cm)
  • Can understand English in order to be properly consented and provide their feedback to the study personnel

Exclusion criteria

Exclusion Criteria:

  • The risks to pregnant women and fetuses are unknown and therefore pregnant women should not participate in the study
  • Other unforeseen disqualifying criteria (such as specific cognitive issues, etc.)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Experimental Prosthetic Liner

    Moisture Management Liner: A prototype liner designed to reduce heat that builds up on the limb. The participant wears this liner at home for about 4 weeks and provides feedback on the prototype.

    Device: Moisture Management Liner

Interventions

  • DeviceMoisture Management Liner

    A prototype liner designed to reduce heat that builds up on the limb.

06

What researchers measure

Primary outcomes

  1. Modified Dermatology Life Quality Index (mDLQI)

    The modified Dermatology Life Quality Index (mDLQI) is a modified version of the Dermatology Life Quality Index (DLQI). The DLQI is a simple questionnaire designed to measure the health-related quality of life of adult patients suffering from various skin diseases. A modified version of the questionnaire (mDLQI) was developed to be more directly applicable to persons with amputation (i.e., revised wording to apply to the skin on their residual limb). The modified survey is scored from 0 to 27, with lower numbers indicating a better outcome.

    Time frame: 4 weeks

07

Results

Posted May 4, 2025

Participant flow

Participant flow — Overall Study
MilestoneExperimental Prosthetic Liner
Started1
Completed1
Not completed0

Outcome measures

PrimaryModified Dermatology Life Quality Index (mDLQI)

The modified Dermatology Life Quality Index (mDLQI) is a modified version of the Dermatology Life Quality Index (DLQI). The DLQI is a simple questionnaire designed to measure the health-related quality of life of adult patients suffering from various skin diseases. A modified version of the questionnaire (mDLQI) was developed to be more directly applicable to persons with amputation (i.e., revised wording to apply to the skin on their residual limb). The modified survey is scored from 0 to 27, with lower numbers indicating a better outcome.

Time frame:
4 weeks
Reported as:
Number · units on a scale
Modified Dermatology Life Quality Index (mDLQI)
units on a scaleExperimental Prosthetic Liner
Modified Dermatology Life Quality Index (mDLQI)7

Adverse events

Collected over Adverse events were monitored/collected during the entire study (about 5 weeks). Participants were told to reach out to study staff immediately if adverse events did occur.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Prosthetic Liner0/1 (0%)0/1 (0%)0/1 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Experimental Prosthetic Liner
<=18 years0
Between 18 and 65 years1
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Experimental Prosthetic Liner
Female0
Male1
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Experimental Prosthetic Liner
Region of Enrollment
Region of Enrollment(participants)Experimental Prosthetic Liner
United States1
Modified Dermatology Life Quality Index (mDLQI)
Modified Dermatology Life Quality Index (mDLQI)(units on a scale)Experimental Prosthetic Liner
Number5
08

Study locations

1 site
  • Liberating Technologies, Inc.
    Holliston, Massachusetts 01746, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Sep 2022, 16 months.

Results were first posted in May 2025, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2021
First posted
Nov 18, 2021
StartActual
May 12, 2021
Primary completionActual
Sep 27, 2022
CompletionActual
Sep 27, 2022
Results first posted
May 4, 2025
Last update
Jun 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05124873
Lead sponsor
Liberating Technologies, Inc.
Collaborators
Vivonics, Inc.
Responsible party
Todd Farrell (Director of Research, Liberating Technologies, Inc.) — Principal investigator
First posted
Nov 18, 2021
Start date
May 12, 2021
Primary completion
Sep 27, 2022
Completion
Sep 27, 2022
Results posted
May 4, 2025
Last update
Jun 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion